Skip to content
Screener

Zevra Therapeutics, Inc. ZVRA Total Liabilities & Equity

Total Liabilities & Equity at other companies

BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
$11.72B+57.2%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$1.26B-3.2%
RFL
Rafael Holdings, Inc.RFL
$91.99M-14.9%
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
$504.61M+187%
Theravance Biopharma logo
Theravance BiopharmaTBPH
$469.77M+10.3%
XER
Xeris Biopharma Holdings, Inc.XERS
$411.91M+23.1%

Other financials

Income statement

See full
Revenue$39.7M+53.3%
Gross profit$38.1M+182%
Operating income$16.8M+124%
Net income$8.8M-88.3%
EPS (diluted)$0.14-88.4%

Balance sheet

See full
Cash & equivalents$145.3M+205%
Total debt$1.5M-97.6%
Total equity$217.7M+85.7%
Total assets$302.7M+18.1%

Cash flow

See full
Operating cash flow$17.0M+573%
CapEx$217.0K+1.9%
Free cash flow$16.8M+541%

Valuation

See full
Market cap$681.73M+6.6%
Enterprise value$537.9M-17.8%
P/E11.7×-230×
P/S-5.3×

Profitability

See full
Gross margin95.5%+23.5pp
Operating margin-103.9%-43.0pp
Net margin42.8%+38.6pp
FCF margin-75%-30.5pp

Returns & leverage

See full
Return on equity34.8%+31.3pp
Debt / equity-0.5×
Current ratio5.2×-2.7×

Where this comes from

Reported directly by Zevra Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.

The source filing: Zevra Therapeutics, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 5:19 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001434647-26-000068
Line itemJune 30,2026December 31,2025
Undesignated preferred stock, $0.0001 par value, 10,000,000 shares authorized, no shares issued or outstanding as of June 30, 2026, or December 31, 2025
Common stock, $0.0001 par value, 250,000,000 shares authorized; 60,917,598 shares issued and 59,341,906 shares outstanding as of June 30, 2026; 58,338,319 shares issued and 56,854,781 shares outstanding as of December 31, 202566
Additional paid-in capital606,264588,458
Treasury stock, at cost(10,983)(10,983)
Accumulated deficit(375,418)(422,060)
Accumulated other comprehensive loss(2,217)(764)
Total stockholders' equity217,652154,657
Total liabilities and stockholders' equity$302,712$284,731

ITEM 1.FINANCIAL STATEMENTS

FAQ

What is Zevra Therapeutics, Inc.'s total liabilities & equity?
Zevra Therapeutics, Inc. (ZVRA) reported total liabilities & equity of $302.71M in Q2 2026.
How has Zevra Therapeutics, Inc.'s total liabilities & equity changed year-over-year?
Zevra Therapeutics, Inc.'s total liabilities & equity increased by 18.1% year-over-year, from $256.28M to $302.71M.
What is the long-term trend for Zevra Therapeutics, Inc.'s total liabilities & equity?
Over 5 years (2020 to 2025), Zevra Therapeutics, Inc.'s total liabilities & equity has grown at a 91.0% compound annual growth rate (CAGR), from $11.21M to $284.73M.
What does total liabilities & equity mean?
Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.

Ask your AI about Zevra Therapeutics, Inc.'s total liabilities & equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude